Leading cancer research organizations to host international cancer immunotherapy conferenceAugust 03, 2015
NEW YORK - The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept. 16-19, 2015.
Titled "Translating Science into Survival," the meeting will cover all areas of inquiry in cancer immunology and immunotherapy, including: immune regulation of T-cell responsiveness, genomic methods for identifying tumor antigens, the tumor microenvironment, T-cell therapies, checkpoint blockade, biomarkers, combinations, and the microbiome. More than 60 talks by acknowledged leaders in these areas will be given.
The full program is available here: http://www.aacr.org/Meetings/Pages/Program-Detail.aspx?EventItemID=54&ItemID=149.
Registration is complimentary for credentialed news media. Members of the media can register using this form: http://www.aacr.org/Documents/15Immuno_RegForm.pdf. Return completed forms to Lauren Riley via email at firstname.lastname@example.org or via fax at 215-446-7291.
Public information officers at medical institutes and cancer centers can also register by contacting Lauren Riley at email@example.com or 215-446-7155.
Those following on social media can join the conversation on Twitter at #cicon15.
American Association for Cancer Research
Related Immunotherapy Articles:
By comparing variations in protein expression in tumor samples from a single melanoma patient, researchers from the Johns Hopkins Bloomberg~Kimmel Institute and the Memorial Sloan-Kettering Cancer Center say their findings have the potential to reveal some of the mechanisms underlying response or resistance to immunotherapy drugs.
Scientists have discovered a new type of immune cell that could predict which lung cancer patients will benefit most from immunotherapy treatment, according to a Cancer Research UK funded study* published today (Monday) in Nature Immunotherapy.
Results of a new clinical study establish particular genetic defects in tumors as clinical indicators for successful response to a type of immunotherapy called PD-1 blockade.
Scientists at Johns Hopkins have created a nanoparticle that carries two different antibodies capable of simultaneously switching off cancer cells' defensive properties while switching on a robust anticancer immune response in mice.
Malignant pleural mesothelioma or MPM is a rare cancer, but its incidence has been rising.
Scientists at the University of Basel in Switzerland have, for the first time, described a new T cell population that can recognize and kill tumor cells.
Duke University researchers found that a molecule called PD-L1, which is blocked by the immunotherapy drug nivolumab, acts not only on immune cells but also on the nerve cells that signal pain.
The preparations that are used for allergen immunotherapy against bee sting allergies do not always contain all the relevant venom components.
A noninvasive PET imaging method that measures granzyme B, a protein released by immune cells to kill cancer cells, was able to distinguish mouse and human tumors that responded to immune checkpoint inhibitors from those that did not respond early in the course of treatment.
In lung cancer patients who were taking immunotherapy drugs targeting the PD-1 pathway, testing for CD8 T cell activation in their blood partially predicted whether their tumors would shrink.
Related Immunotherapy Reading:
A Cure Within: Scientists Unleashing The Immune System to Kill Cancer
by Neil Canavan (Author)
The way we treat cancer is about to change forever. This revolution--and it is precisely that--was sparked not by the invention of a new drug, but by the evolution of an entirely new way of thinking about and managing cancer. Going forward, doctors will not use pharmaceuticals to attack tumors--not directly. Rather, the oncologist will treat the patient's immune system with a drug, and then the patient will treat the tumor.
Based entirely on interviews with the investigators, this book is the story of the immuno-oncology pioneers. It's a story of failure, resurrection, and success.... View Details
The Basics of Cancer Immunotherapy
by Haidong Dong (Editor), Svetomir N. Markovic (Editor)
This book provides patients and their physicians (especially “non-oncologist” health care providers) with a clear and concise introduction to cancer immunotherapy, which, unlike traditional forms of cancer therapy, acts by boosting the patient’s own immune system to fight cancer. The unique features of cancer immunotherapy make its management, monitoring and side-effects different from those of traditional cancer therapy. Especially novel are the side effects of cancer immunotherapy, necessitating greater awareness for both patients and physicians in order to minimize complications... View Details
Curing Cancer with Immunotherapy: How it happened a century ago, what we learned as we attempted it, and why it is possible today.
by Rene Chee (Author), Edward Chee (Author)
Four out of every ten people will be diagnosed with cancer sometime during their lifetime. 600,000 cancer patients in the U.S. will die every year.
For decades, standard therapies have remained powerless against advanced cancer. But in the 1890s, an American surgeon showed that terminal patients could be cured by stimulating their immune systems. The treatment? A concoction of dead bacteria known as Coley’s Toxins.
This is the real-life story of Rene Chee, a biologist diagnosed with an aggressive cancer while working at Stanford University. After conventional treatment, she realizes... View Details
Cancer Immunotherapy Principles and Practice
by Lisa H. Butterfield PhD (Editor), Howard L. Kaufman MD FACS (Editor), Francesco M. Marincola MD FACS (Editor)
“Drs. Butterfield, Kaufman and Marincola on behalf of the SITC have created a comprehensive must-have resource covering the basic and translational science behind approved and investigational immune therapies, and disease-by-disease clinical application of the therapies, written by leaders in the field. The textbook will be highly valuable reading for those just entering the field and for experienced scientists and clinicians looking to expand their knowledge base.” ―Mario Sznol, MD, Professor of Medicine (Medical Oncology), Yale School of Medicine, New Haven,... View Details
The Living Cure: The Promise of Cancer Immunotherapy
by Dr. David Eifrig Jr. (Author), The Stansberry Research Team (Author)
In The Living Cure, you'll find out: - A real, science-backed alternative to poisonous chemotherapy and radiation. - Where to go if anyone you know is faced with this horrible disease. - How to access incredible treatments not available to the general public. - One decision that could instantly double your chance of survival. - And much more... Dr. David Eifrig, Jr. is certain this research could save your life or the life of a loved one. View Details
Cancer Chemotherapy, Immunotherapy and Biotherapy
by Bruce A. Chabner MD (Author), Dan L. Longo MD (Author)
Publisher's Note: Products purchased from 3rd Party sellers are not guaranteed by the Publisher for quality, authenticity, or access to any online entitlements included with the product.
Thoroughly revised and reformatted, the sixth edition of Cancer Chemotherapy, Immunotherapy and Biotherapy reflects recent significant changes in cancer treatment. This newly streamlined edition contains full-color illustrations, more tables for quick reference, and new immunotherapy and molecular targeted therapy content that brings you fully up to date with the state of the art in... View Details
Immunotherapy in Translational Cancer Research (Translational Oncology)
by Laurence J. N. Cooper (Editor), Elizabeth A. Mittendorf (Editor), Judy Moyes (Editor), Sabitha Prabhakaran (Editor)
A guide to state-of-the-art cancer immunotherapy in translational cancer research
A volume in the Translational Oncology series, Immunotherapy in Translational Cancer Research explores the recent developments in the role that immunotherapy plays in the treatment of a wide range of cancers. The editors present key concepts, illustrative examples, and suggest alternative strategies in order to achieve individualized targeted therapy. Comprehensive in scope, Immunotherapy in Translational Cancer Research reviews the relevant history, current state,... View Details
Cancer Immunotherapy, Second Edition: Immune Suppression and Tumor Growth
by George C. Prendergast (Editor), Elizabeth M. Jaffee (Editor)
There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer, and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumor immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic... View Details
Immunotherapy (Advances in Experimental Medicine and Biology)
by Aung Naing (Editor), Joud Hajjar (Editor)
In the last decade, immunotherapy has revolutionized the practice of medicine in the field of oncology. This book, Immunotherapy, highlights the immunotherapeutic approaches currently in use and strategies to overcome the associated challenges. As comprehensive knowledge of basic immunology in the context of tumor biology is required to move further along the line of development in translational science, this book provides an overview of the cellular components of the immune system that interact with each other to provide a successful immune response.Immunotherapy offers promising... View Details
Immunotherapy of Cancer (Cancer Drug Discovery and Development)
by Mary L. Disis (Editor)
Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The... View Details